



Synta Pharmaceuticals to Participate in the 2007 RBC Capital Markets Healthcare Conference

December 3, 2007

Company to Webcast Panel Presentation on December 12

LEXINGTON, Mass.--(BUSINESS WIRE)--Dec. 3, 2007--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that President and CEO Safi Bahcall, Ph.D., will participate in a panel discussion on Novel Cancer Targets at the 2007 RBC Capital Markets Healthcare Conference on Wednesday, December 12, 2007 at 2:30 pm (ET) at The Westin New York at Times Square.

A live audio webcast and replay of the panel discussion will be available on the "Investors" section of the Company's website, www.syntapharma.com.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and drug discovery capabilities. Synta has a partnership with GlaxoSmithKline for the joint development and commercialization of its lead investigational drug candidate, elesclomol, which is in a global, pivotal Phase 3 clinical trial for the treatment of metastatic melanoma. For more information, please visit www.syntapharma.com.

CONTACT: Synta Pharmaceuticals Corp.
Rob Kloppenburg, 781-541-7125
or
MacDougall Biomedical Communications
Doug MacDougall, 508-647-0209

SOURCE: Synta Pharmaceuticals Corp.